Importantly, we showcase that the exogenous administration of recombinant human IL-37 protein in EAE mice ameliorated the clinical and histopathological signs of the disease, suggesting the therapeutic potential of IL-37 in MS. This evidence concerns the gene IL37 and myeloid sarcoma.